Pharmaceuticals (NASDAQ: ARNA ) and VIVUS Inc (NASDAQ: VVUS ) need no introduction. 2012 was ..... for Belviq on June 27, 2012. VIVUS 's Qsymia, a combination of phentermine ..... road to approval Both Arena and VIVUS saw their stocks bid up several
By Alexander Maxwell : Having previously updated the investment community in part 3 of my Biotechnology Catalysts series, the purpose of this article is to help give investors an idea of the upcoming biotechnology catalysts through the end of September. It can be hard for investors to be able to ...
week is that for the first time (using IMS Health numbers) Belviq sales were above the levels reported for Vivus 's (NASDAQ: VVUS ) Qsymia. Belviq edged out Qsymia by a handful of scripts via the fact that week over week numbers for Qsymia
number of scripts sold. I analyzed the data for Belviq from Arena Pharmaceuticals (NASDAQ: ARNA ) and Qsymia from Vivus (NASDAQ: VVUS ). There are a couple of items that investors should consider when looking at what I am presenting here: An adverse
By Spencer Osborne : Sales of the anti-obesity pill Belviq from Arena Pharmaceuticals (NASDAQ: ARNA ) continue to buck the seasonality of the weight loss sector with a 3.6% week over week gain. While 3.6% may not seem impressive, investors must consider that the second half of the year typically ...
By Spencer Osborne : Vivus (NASDAQ: VVUS ) announced its quarterly earnings today and beat the street by $0 ..... second quarter of 2013. For STENDRAÂ® and SPEDRAâ„¢, Vivus recognized $4.2 million in license and milestone revenue
VIVUS Inc (NASDAQ: VVUS ) Q2 2014 Earnings Conference Call August ..... ladies and gentlemen, and welcome to the VIVUS Second Quarter 2014 Financial Results Teleconference ..... remind you that during this conference call, VIVUS will Complete Story »
Vivus ( VVUS -0.4% ) Q2 results : Revenues: $21.9M (+295.4%); Qsymia Sales: $11.0M (+100.0%); Operating Expenses
The following audio is from a conference call that will begin on August 07, 2014 at 16:30 PM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »
By Spencer Osborne : Orexigen (NASDAQ: OREX ) announced its Q2 financial results this morning and the loss of $0.21 cents came in line with expectations. The equity moved up early in the session because of positive outlooks for the anti-obesity drug NB32, also known as Contrave. Orexigen is ...